Pharmacotherapy for the treatment of aggressive behavior in general adult psychiatry: A systematic review

Journal of Clinical Psychiatry

Volumn 67, Issue 7, 2006, Pages 1013-1024

  Goedhard, Laurette E ^a,b   Stolker, Joost J ^a,b   Heerdink, Eibert R ^b   Nijman, Henk L I ^c   Olivier, Berend ^b,d,e   Egberts, Toine C G ^b,f,g  

^a Altrecht Institute for Mental Healthcare   (Netherlands)

^b UTRECHT UNIVERSITY   (Netherlands)

^c RADBOUD UNIVERSITY NIJMEGEN   (Netherlands)

^d UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

^e YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^f GGZ Midden Brabant   (Netherlands)

^g CPRLab   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

AMITRIPTYLINE; ANTICONVULSIVE AGENT; ANTIDEPRESSANT AGENT; ATYPICAL ANTIPSYCHOTIC AGENT; BENZODIAZEPINE; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CARBAMAZEPINE; CHLORDIAZEPOXIDE; CITALOPRAM; CLOZAPINE; FLUOXETINE; FLUVOXAMINE; HALOPERIDOL; IMIPRAMINE; LITHIUM; METHYLPHENIDATE; NADOLOL; NEUROLEPTIC AGENT; OLANZAPINE; PHENELZINE; PINDOLOL; PROPRANOLOL DERIVATIVE; PSYCHOTROPIC AGENT; RISPERIDONE; SERTRALINE; TOPIRAMATE; VALPROATE SEMISODIUM; VALPROIC ACID;

AGGRESSION; ANGER; AUTISM; BORDERLINE STATE; BRADYKINESIA; BRAIN DISEASE; BRONCHITIS; BRONCHOSPASM; CLINICAL PRACTICE; CLINICAL TRIAL; DEPRESSION; DIARRHEA; DROWSINESS; DRUG ACTIVITY; DRUG EFFICACY; EVIDENCE BASED MEDICINE; EXTRAPYRAMIDAL SYMPTOM; HEADACHE; HEMATOLOGIC DISEASE; HOSTILITY; HUMAN; HYPERTENSION; HYPOKINESIA; HYPOTENSION; MEDICAL LITERATURE; MOTOR DYSFUNCTION; NAUSEA; PERSONALITY DISORDER; POSTTRAUMATIC STRESS DISORDER; PRIORITY JOURNAL; PSYCHIATRY; REVIEW; SCHIZOPHRENIA; SEDATION; SEIZURE; SIDE EFFECT; SWEATING; SYNCOPE; SYSTEMATIC REVIEW; TREATMENT OUTCOME; UNSPECIFIED SIDE EFFECT; VIOLENCE; WEIGHT GAIN; WEIGHT REDUCTION;

EID: 33747199039     PISSN: 01606689     EISSN: None     Source Type: Journal    
DOI: 10.4088/JCP.v67n0702     Document Type: Review

References (90)

1. Nijman HL, Palmstierna T, Almvik R, et al. Fifteen years of research with the Staff Observation Aggression Scale: a review. Acta Psychiatr Scand 2005;111:12-21
2. Hunter M, Carmel H. The cost of staff injuries from inpatient violence. Hosp Community Psychiatry 1992;43:586-588
3. Caldwell A. Hospital accountability: perceptions and costs. Front Health Serv Manage 1992;8:38-40
4. Shah AK, Fineberg NA, James DV. Violence among psychiatric inpatients. Acta Psychiatr Scand 1991;84:305-309
5. Nijman H, Bowers L, Oud N, et al. Psychiatric nurses' experiences with inpatient aggression. Aggress Behav 2005;31:217-227
6. Posternak MA, Zimmerman M. Anger and aggression in psychiatric outpatients. J Clin Psychiatry 2002;63:665-672
7. Steinert T. Prediction of inpatient violence. Acta Psychiatr Scand Suppl 2002;412:133-141
8. Harris GT, Rice ME. Risk appraisal and management of violent behavior. Psychiatr Serv 1997;48:1168-1176
9. Kennedy J, Harrison J, Hillis T, et al. Analysis of violent incidents in a regional secure unit. Med Sci Law 1995;35:255-260
10. Owen C, Tarantello C, Jones M, et al. Repetitively violent patients in psychiatric units. Psychiatr Serv 1998;49:1458-1461
11. Smoot SL, Gonzales JL. Cost-effective communication skills training for state hospital employees. Psychiatr Serv 1995;46:819-822
12. Morrison EF. An evaluation of four programs for the management of aggression in psychiatric settings. Arch Psychiatr Nurs 2003;17:146-155
13. Needham I. A Nursing Intervention to Handle Patient Aggression: The Effectiveness of a Training Course in the Management of Aggression. Maastricht, the Netherlands: Maastricht University; 2004
14. Soliman AE, Reza H. Risk factors and correlates of violence among acutely ill adult psychiatric inpatients. Psychiatr Serv 2001;52:75-80
15. Pabis DJ, Stanislav SW. Pharmacotherapy of aggressive behavior. Ann Pharmacother 1996;30:278-287
16. Fava M. Psychopharmacologic treatment of pathologic aggression. Psychiatr Clin North Am 1997;20:427-451
17. Lindenmayer JP, Kotsaftis A. Use of sodium valproate in violent and aggressive behaviors: a critical review. J Clin Psychiatry 2000;61:123-128
18. Starfield B. Quality-of-care research: internal elegance and external relevance. JAMA 1998;280:1006-1008
19. Zarin DA, Young JL, West JC. Challenges to evidence-based medicine: a comparison of patients and treatments in randomized controlled trials with patients and treatments in a practice research network. Soc Psychiatry Psychiatr Epidemiol 2005;40:27-35
20. Slavin RE. Best evidence synthesis: an intelligent alternative to meta-analysis. J Clin Epidemiol 1995;48:9-18
21. van der Windt DAWM, van der Heijden GJMG, van den Berg SGM, et al. Ultrasound therapy for musculoskeletal disorders: a systematic review. Pain 1999;81:257-271
22. Smidt N, Assendelft WJ, van der Windt DA, et al. Corticosteroid injections for lateral epicondylitis: a systematic review. Pain 2002;96:23-40
23. Jadad AR, Moore RA, Carroll D, et al. Assessing the quality of reports of randomized clinical trials: is blinding necessary? Control Clin Trials 1996;17:1-12
24. Mulrow CD, Oxman AD. Cochrane Collaboration Handbook. In: The Cochrane Library, Issue 4, 1997. Chichester, England: Wiley
25. Cohen J, ed. Statistical Power Analysis for the Behavioral Sciences. Hillsdale, NJ: Lawrence Erlbaum Associates, Inc; 1988
26. Altman DG, Bland JM. Detecting skewness from summary information. BMJ 1996;313:1200
27. Min SK, Rhee CS, Kim CE, et al. Risperidone versus haloperidol in the treatment of chronic schizophrenic patients: a parallel group double-blind comparative trial. Yonsei Med J 1993;34:179-190
28. Czobor P, Volavka J, Meibach RC. Effect of risperidone on hostility in schizophrenia. J Clin Psychopharmacol 1995;15:243-249
29. Dorrego MF, Canevaro L, Kuzis G, et al. A randomized, double-blind, crossover study of methylphenidate and lithium in adults with attention-deficit/hyperactivity disorder: preliminary findings. J Neuropsychiatry Clin Neurosci 2002;14:289-295
30. Allan ER, Alpert M, Sison CE, et al. Adjunctive nadolol in the treatment of acutely aggressive schizophrenic patients. J Clin Psychiatry 1996;57:455-459
31. Alpert M, Allan ER, Citrome L, et al. A double-blind, placebo-controlled study of adjunctive nadolol in the management of violent psychiatric patients. Psychopharmacol Bull 1990;26:367-371
32. Caspi N, Modai I, Barak P, et al. Pindolol augmentation in aggressive schizophrenic patients: a double-blind crossover randomized study. Int Clin Psychopharmacol 2001;16:111-115
33. Citrome L, Casey DE, Daniel DG, et al. Adjunctive divalproex and hostility among patients with schizophrenia receiving olanzapine or risperidone. Psychiatr Serv 2004;55:290-294
34. Citrome L, Volavka J, Czobor P, et al. Effects of clozapine, olanzapine, risperidone, and haloperidol on hostility among patients with schizophrenia. Psychiatr Serv 2001;52:1510-1514
35. Davidson JR, Landerman LR, Farfel GM, et al. Characterizing the effects of sertraline in post-traumatic stress disorder. Psychol Med 2002;32:661-670
36. Davidson JR, McLeod MN, Turnbull CD, et al. A comparison of phenelzine and imipramine in depressed inpatients. J Clin Psychiatry 1981;42:395-397
37. de la Fuente JM, Lotstra F. A trial of carbamazepine in borderline personality disorder. Eur Neuropsychopharmacol 1994;4:479-486
38. Fassino S, Leombruni P, Daga G, et al. Efficacy of citalopram in anorexia nervosa: a pilot study. Eur Neuropsychopharmacol 2002;12:453-459
39. Fava M, Nierenberg AA, Quitkin FM, et al. A preliminary study on the efficacy of sertraline and imipramine on anger attacks in atypical depression and dysthymia. Psychopharmacol Bull 1997;33:101-103
40. Frankenburg F, Zanarini M. Divalproex sodium treatment of women with borderline personality disorder and bipolar II disorder: a double-blind placebo-controlled pilot study. J Clin Psychiatry 2002;63:442-446
41. Lipman RS, Covi L, Rickels K, et al. Imipramine and chlordiazepoxide in depressive and anxiety disorders, 1: efficacy in depressed outpatients. Arch Gen Psychiatry 1986;43:68-77
42. Maoz G, Stein D, Meged S, et al. The antiaggressive action of combined haloperidol-propranolol treatment in schizophrenia. Eur Psychologist 2000;5:312-325
43. Mattes JA. Comparative effectiveness of carbamazepine and propranolol for rage outbursts. J Neuropsychiatry Clin Neurosci 1990;2:159-164
44. McDougle CJ, Naylor ST, Cohen DJ, et al. A double-blind, placebo-controlled study of fluvoxamine in adults with autistic disorder. Arch Gen Psychiatry 1996;53:1001-1008
45. Monnelly EP, Ciraulo DA, Knapp C, et al. Low-dose risperidone as adjunctive therapy for irritable aggression in posttraumatic stress disorder. J Clin Psychopharmacol 2003;23:193-196
46. Nickel KM, Nickel C, Kaplam P, et al. Treatment of aggression with topiramate in male borderline patients: a double-blind, placebo-controlled study. Biol Psychiatry 2005;57:495-499
47. Ratey JJ, Sorgi P, O'Driscoll GA, et al. Nadolol to treat aggression and psychiatric symptomatology in chronic psychiatric inpatients: a double-blind, placebo-controlled study. J Clin Psychiatry 1992;53:41-46
48. Rinne T, van den Brink W, Wouters L, et al. SSRI treatment of borderline personality disorder: a randomized, placebo-controlled clinical trial for female patients with borderline personality disorder. Am J Psychiatry 2002;159:2048-2054
49. Salzman C, Wolfson AN, Schatzberg A, et al. Effect of fluoxetine on anger in symptomatic volunteers with borderline personality disorder. J Clin Psychopharmacol 1995;15:23-29
50. Soloff PH, Cornelius J, George A, et al. Efficacy of phenelzine and haloperidol in borderline personality disorder. Arch Gen Psychiatry 1993;50:377-385
51. Soloff PH, George A, Nathan S, et al. Amitriptyline versus haloperidol in borderlines: final outcomes and predictors of response. J Clin Psychopharmacol 1989;9:238-246
52. Vartiainen H, Tiihonen J, Putkonen A, et al. Citalopram, a selective serotonin reuptake inhibitor, in the treatment of aggression in schizophrenia. Acta Psychiatr Scand 1995;91:348-351
53. Zanarini MC, Frankenburg FR. Olanzapine treatment of female borderline personality disorder patients: a double-blind, placebo-controlled pilot study. J Clin Psychiatry 2001;62:849-854
54. Zanarini MC, Frankenburg FR, Parachini EA. A preliminary, randomized trial of fluoxetine, olanzapine, and the olanzapine-fluoxetine combination in women with borderline personality disorder. J Clin Psychiatry 2004;65:903-907
55. Hollander E, Allen A, Lopez RP, et al. A preliminary double-blind, placebo-controlled trial of divalproex sodium in borderline personality disorder. J Clin Psychiatry 2001;62:199-203
56. Hollander E, Tracy KA, Swann AC, et al. Divalproex in the treatment of impulsive aggression: efficacy in cluster B personality disorders. Neuropsychopharmacology 2003;28:1186-1197
57. Coccaro EF, Kavoussi RJ. Fluoxetine and impulsive aggressive behavior in personality-disordered subjects. Arch Gen Psychiatry 1997;54:1081-1088
58. van der Kolk BA, Dreyfuss D, Michaels M, et al. Fluoxetine in posttraumatic stress disorder. J Clin Psychiatry 1994;55:517-522
59. Blin O, Azorin JM, Bouhours P. Antipsychotic and anxiolytic properties of risperidone, haloperidol, and methotrimeprazine in schizophrenic patients. J Clin Psychopharmacol 1996;16:38-44
60. Peuskens J. Risperidone in the treatment of patients with chronic schizophrenia: a multi-national, multi-centre, double-blind, parallel-group study versus haloperidol. Risperidone Study Group. Br J Psychiatry 1995;166:712-726
61. Marder SR, Davis JM, Chouinard G. The effects of risperidone on the five dimensions of schizophrenia derived by factor analysis: combined results of the North American trials. J Clin Psychiatry 1997;58:538-546
62. Yudofsky SC, Silver JM, Jackson W, et al. The Overt Aggression Scale for the objective rating of verbal and physical aggression. Am J Psychiatry 1986;143:35-39
63. Kay SR, Fiszbein A, Opler LA. The Positive and Negative Syndrome Scale (PANSS) for schizophrenia. Schizophr Bull 1987;13:261-276
64. Arntz A, van den Hoorn M, Cornelis J, et al. Reliability and validity of the Borderline Personality Disorder Severity Index. J Personal Disord 2003;17:45-59
65. Palmstierna T, Wistedt B. Staff Observation Aggression scale, SOAS: presentation and evaluation. Acta Psychiatr Scand 1987;76:657-663
66. Wistedt B, Rasmussen A, Pedersen L, et al. The development of an observer-scale for measuring social dysfunction and aggression. Pharmacopsychiatry 1990;23:249-252
67. Fava M, Rosenbaum JF, McCarthy M, et al. Anger attacks in depressed outpatients and their response to fluoxetine. Psychopharmacol Bull 1991;27:275-279
68. Buss AH, Perry M. The Aggression Questionnaire. J Pers Soc Psychol 1992;63:452-459
69. Buss AH, Durkee A. An inventory for assessing different kinds of hostility. J Consult Psychol 1957;21:343-349
70. Overall JE, Gorham DR. The Brief Psychiatric Rating Scale. Psychol Rep 1962;10:799-812
71. Brown GL, Goodwin FK, Ballenger JC, et al. Aggression in humans correlates with cerebrospinal fluid amine metabolites. Psychiatry Res 1979;1:131-139
72. Guy W. ECDEU Assessment Manual for Psychopharmacology. US Dept Health, Education, and Welfare publication (ADM) 76-338. Rockville, Md: National Institute of Mental Health; 1976
73. Davidson JRT, Book SW, Colket JT, et al. Assessment of a new self-rating scale for post-traumatic stress disorder. Psychol Med 1997;27:153-160
74. Lipman RS, Covi L, Shapiro AK. The Hopkins Symptom Checklist (HSCL): factors derived from the HSCL-90. J Affect Disord 1979;1:9-24
75. Lorr M, Klett CJ. Inpatient Multidimensional Psychiatric Scale: Manual. Palo Alto, Calif: Consulting Psychologists Press; 1966
76. Siegel JM. The Multidimensional Anger Inventory. J Pers Soc Psychol 1986;51:191-200
77. Coccaro EF, Harvey PD, Kupsaw-Lawrence E, et al. Development of neuropharmacologically based behavioral assessments of impulsive aggressive behavior. J Neuropsychiatry Clin Neurosci 1991;3:S44-S51
78. Blin O, Azorin JM, Lecrubier Y, et al. The Psychotic Anxiety Scale (PAS). Evaluation of inter-rater reliability and correspondence factorial analysis [in French]. Encephale 1989;15:543-547
79. McNair DM, Lorr M, Droppleman LF. Manual for the Profile of Mood States. San Diego, Calif: Educational and Industrial Testing Service; 1971
80. Spielberger CD. State-Trait Anger Expression Inventory, Research Edition: Professional Manual. Odessa, Fla: Psychological Assessment Resources; 1988
81. Spielberger CD, Barker L, Russell S, et al. Preliminary Manual for Personality Inventory (STPI). Tampa, Fla: University of South Florida; 1979
82. Spielberger CD, Jacobs G, Russel S, et al. Assessment of anger: the State-Trait Anger Scale. In: Butcher JN, Spielberger CD, eds. Advances in Personality Assessments, vol 2. Hillsdale, NJ: Lawrence Erlbaum Associates; 1983:159-187
83. Teicher MH, Glod CA. Pharmacotherapy of patients with borderline personality disorder. Hosp Community Psychiatry 1989;40:887-889
84. Steadman HJ, Silver E, Monahan J, et al. A classification tree approach to the development of actuarial violence risk assessment tools. Law Hum Behav 2000;24:83-100
85. Edlund MJ, Craig TJ, Richardson MA. Informed consent as a form of volunteer bias. Am J Psychiatry 1985;142:624-627
86. Deb S, Crownshaw T. The role of pharmacotherapy in the management of behaviour disorders in traumatic brain injury patients. Brain Inj 2004;18:1-31
87. Kane JM, Leucht S, Carpenter D, et al. Expert consensus guideline series: optimizing pharmacologic treatment of psychotic disorders. Introduction: methods, commentary, and summary. J Clin Psychiatry 2003;64(suppl 12):5-19
88. Heerdink ER, Stolker JJ, Meijer WE, et al. Need for medicine-based evidence in pharmacotherapy [letter]. Br J Psychiatry 2004;184:452
89. Dieppe P, Bartlett C, Davey P, et al. Balancing benefits and harms: the example of non-steroidal anti-inflammatory drugs. BMJ 2004;329:31-34
90. March JS, Silva SG, Compton S, et al. The case for practical clinical trials in psychiatry. Am J Psychiatry 2005;162:836-846